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Abstract
There has been increasing interest in open artery syndrome, also known as ischemia with non-obstructive coronary arteries
(INOCA). INOCA has been increasingly recognized as a heterogeneous clinical entity. Diagnostic evaluation of this heterogeneous entity, including invasive assessment, remains key to diagnose this clinical condition and provide the appropriate treatment. Importantly, medical stratification based on the type of INOCA has shown benefit in improving the symptoms in these
patients, as illustrated in the CorMicA trial. The Women’s IschemiA Trial to Reduce Events in Non-ObstRuctIve CORonary
Artery Disease (WARRIOR) is another promising landmark trial that is currently enrolling patients and will address some of
the unanswered questions for management of women with INOCA. In this review, we discuss the pathophysiology, management
options, knowledge gaps, and future directions while highlighting the rationale and design of the ongoing WARRIOR trial.
Key Points
Ischemia with non-obstructive coronary arteries
(INOCA) is increasingly recognized as a heterogeneous
clinical entity.
Coronary microvascular dysfunction (CMD) is divided
into two sub-types: structural and functional.
Medical therapy stratification based on INOCA sub-type
demonstrated improvement in angina in these patients, as
shown in the CorMicA trial.
The WARRIOR is an ongoing landmark trial randomizing patients with INOCA to intensive medical treatment
versus usual care and assessing the impact on clinical
outcomes.
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1 Introduction
Coronary artery disease (CAD) remains a leading cause
of death and disability in the USA and worldwide, even
among women [1]. Traditionally, CAD has been mechanistically linked with a flow-limiting stenosis in an epicardial
coronary artery due to obstruction caused by atherosclerotic
plaque. There has been growing interest in the entity of nonobstructive CAD (i.e., epicardial coronary artery stenosis
<50% diameter or non-flow–limiting), which is very frequent
among patients presenting with symptoms and/or signs of
myocardial ischemia [2–5]. Clinically, these findings may be
defined together as “open artery ischemia” or ischemia with
no obstructive coronary arteries (INOCA). This syndrome
is often a direct result of inadequate coronary perfusion due
to limitations of the microvasculature to appropriately match
blood flow with myocardial oxygen demands [2–5]. Although
previously viewed as “benign”, recognition of INOCA has
become relevant since accumulating evidence documents an
elevated risk for poor quality of life, major adverse cardiac
event (MACE), and also burdens on the healthcare system
with few promising treatments at present [3, 5–9].

2 Epidemiology
INOCA is not an uncommon condition. In an analysis
from the National Cardiovascular Data Registry's CathPCI
Registry of 661,063 patients undergoing elective coronary
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angiography, the majority (58.4%) had evidence of nonobstructive CAD [8]. Patients with non-obstructive CAD
were younger, more likely to be women, and obese or overweight. In addition, the prevalence of traditional cardiovascular risk factors such as diabetes mellitus and hypertension were comparable to groups with obstructive CAD [8,
9]. In a Danish study of 11,223 patients with stable angina
pectoris, 15.2% had non-obstructive CAD. Non-obstructive
CAD was associated with a 52% excess risk for all-cause
mortality (hazards ratio [HR] 1.52, 95% confidence interval
[CI] 1.24–1.88) and MACE (HR 1.52, 95% CI 1.24–1.88)
compared with a reference population without ischemic
heart disease [4]. These findings were further supported by
another study of 37,674 veterans which showed that nonobstructive CAD was associated with increased risk of allcause mortality and myocardial infarction at 1 year, which
was exacerbated by increasing numbers of vessels affected
with non-obstructive CAD [2]. It is important to note that
the risk of MACE increased with increasing degrees of CAD
(HR 1.52, 95% CI 1.27–1.83) among patients with INOCA
and normal coronary arteries as well as patients with diffuse non-obstructive CAD (HR 1.85, 95% CI 1.51–2.28).
For all-cause mortality, normal coronary arteries and diffuse non-obstructive CAD were associated with HRs of 1.29
(1.07–1.56) and 1.52 (1.24–1.88), respectively [4].

3 Pathophysiology of INOCA and Potential
Targets for Management
INOCA was defined by a consensus statement from the
European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation, which was also
endorsed by the Coronary Vasomotor Disorders International Study (COVADIS) group, as a demand-supply
mismatch of coronary artery blood flow leading to transient or recurrent cardiac chest pain related to myocardial ischemia. The mismatch between blood supply and
myocardial oxygen demands may be caused by coronary
microvascular dysfunction and/or epicardial coronary
artery spasm, typically in the setting of non-obstructive
coronary atherosclerosis. In this setting, the working group
provided diagnostic criteria for microvascular angina to
include all of the following: (1) Symptoms of myocardial
ischemia, (2) Absence of obstructive CAD (< 50% diameter reduction or FFR > 0.80), (3) Objective evidence of
myocardial ischemia, and 4) Evidence of impaired coronary microvascular function [10].
The underlying mechanisms implicated in the pathophysiology for INOCA are multifactorial [9, 11]. Coronary
microvascular dysfunction (CMD) remains a central component in the pathophysiology of INOCA and is defined
by Camici and Crea as either coronary vascular smooth

muscle dysfunction or endothelial dysfunction [12]. CMD
may be broadly classified into two endotypes: structural
CMD and functional CMD [13]. Structural CMD is characterized by reduced microvascular conductance and
impaired oxygen delivering capacity to the myocardium.
The decreased microvascular conductance is a result of
inward remodeling of small-sized coronary arterioles,
while the impaired oxygen delivering capacity to the myocardium is a product of myocardial capillary rarefaction
or low coronary microvascular density [14]. Both inward
remodeling of small-sized coronary arterioles and myocardial capillary rarefaction are commonly seen in structural CMD. Other comorbidities, such as diabetes mellitus
and hypertension, have long been linked with CMD and
exacerbate the detrimental effects of structural CMD [9,
15–19]. Not uncommonly, atherosclerosis is observed in a
significant proportion of patients with INOCA on intravascular imaging [9, 15]. In these cases, intravascular imaging has documented that positive remodeling conceals the
atherosclerotic plaque. By contrast, functional CMD does
not result from inward remodeling of small-sized coronary
arterioles, but rather represents an impaired flow-mediated/endothelium-dependent vasodilation of the microvasculature [13]. Coronary arterioles’ insensitivity to vasodilatory stimuli and hypersensitivity to vasoconstrictive
stimuli amplify, and thus diffuse stenoses in the microvasculature can be widely seen. Like structural CMD, several
comorbidities are observed among patients with functional
CMD. Chronic inflammation, documented by elevated
high-sensitivity C-reactive protein, augments the adverse
effects of structural and functional CMD and accentuates
the degree of angina [20, 21]. Furthermore, cardiac, and
perhaps central, autonomic nervous system activation is
associated with intensification of the detrimental effects of
functional CMD by impairing modulation between vasodilatory and vasoconstrictive stimuli (Fig. 1). Vasospastic
angina is the clinical manifestation of myocardial ischemia
caused by dynamic epicardial coronary obstruction caused
by a vasomotor disorder. Epicardial vessel spasm typically occurs when hyper-reactive epicardial coronary vessel segment undergoes maximal contraction when exposed
to vasoconstrictor stimuli, which include smoking, cold
weather, drugs, peaks in blood pressure, emotional stress,
and hyperventilation. Concomitant vasospastic angina and
CMD are associated with worse prognosis [10]. Table 1
summarizes endotypes of INOCA.
It is worth mentioning that there seems to be an association between INOCA and heart failure with preserved ejection fraction (HFpEF). Data from endomyocardial biopsy
samples from patients with HFpEF showed that an inflamed
microvascular endothelium allows monocyte migration
and transforming growth factor (TGF)-β release that promotes the differentiation of fibroblasts into myofibroblasts,
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promoting collagen production and cross-linking. Furthermore, this pro-inflammatory and pro-oxidative state may
render the dysfunctional coronary microvasculature more
vulnerable to repeat episodes of myocardial ischemia and
micro-infarcts leading to interstitial fibrosis and shift in substrate metabolism, ultimately leading to HFpEF in humans
[22–24]. We are currently investigating CMD as a preHFpEF syndrome (ClinicalTrials.gov NCT03876223).

Table 1  Summary of endotypes of INOCA
Endotype

Definition/characteristic

CMD

CMD is defined by Camici and Crea as either
coronary vascular smooth muscle dysfunction or endothelial dysfunction. CMD may be
broadly classified into two endotypes: structural CMD and functional CMD. Structural
CMD is characterized by reduced microvascular conductance and impaired oxygen
delivering capacity to the myocardium due to
inward remodeling of small-sized coronary
arterioles. By contrast, functional CMD
results from an impaired flow-mediated
endothelium-dependent vasodilation of
the microvasculature with insensitivity to
vasodilatory stimuli and hypersensitivity to
vasoconstrictive stimuli amplify [10, 12, 13,
22]
Vasospastic angina is the clinical manifestation
of myocardial ischemia caused by dynamic
epicardial coronary obstruction secondary
to a vasomotor disorder. Epicardial vessel
spasm typically occurs when hyper-reactive
epicardial coronary vessel segment undergoes
maximal contraction when exposed to vasoconstrictor stimuli, which include smoking,
cold weather, drugs, peaks in blood pressure,
emotional stress, and hyperventilation [10,
22]

4 Management of INOCA
It is important that providers and patients understand the
“natural” history of INOCA patients that was recently presented in the CIAO-Ischemia ancillary study [25]. That
INOCA cohort had a degree of stress inducible wall motion
abnormalities similar to that of the concurrently enrolled
ISCHEMIA trial participants with obstructive CAD. But
despite no specific treatments, improvement in the ischemiainduced wall motion abnormalities and improvement in
angina occurred in about half of INOCA patients at 1 year,
but interestingly these responses were not correlated. Such
results highlight the complexities of INOCA pathophysiology as well the multifactorial mechanisms of angina.
With this background, we recommend that management
should be patient-centered with a multidisciplinary care
approach focusing on lifestyle modification and aggressive
risk factor control, including blood pressure, glycemic and
lipid management, with smoking cessation and exercise/
activity promotion [26]. Treatment of underlying comorbidities and avoiding known triggering factors are also key
[26]. Studies have shown benefit of certain medications in
this heterogenous group of patients. Table 2 summarizes the
evidence supporting these medications in INOCA. While
Fig. 1  Summary of endotypes
of coronary microvascular
dysfunction (CMD)

Vasospastic angina

CMD coronary microvascular dysfunction

beta-blockers, calcium channel blockers, ranolazine and
ivabradine may have benefit in certain patients, subgroups
with impaired vasodilation and/or excessive vasoconstriction may benefit more from calcium channel blockers and/
or nitrates [26–28].
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4.1 Conventional Therapies
Calcium channel blockers are vasodilators, which help
prevent epicardial and microvascular coronary vasospasm.
Verapamil, diltiazem, nifedipine, amlodipine, and nisoldipine have all decreased symptoms and increased effort
tolerance in trials of INOCA patients, compared with placebo [29–32]. Their combination with a statin appeared particularly effective [30]. These results suggest that at least a
subgroup of INOCA patients benefits from calcium channel
blockers. However, their effect on CFR itself appears to be
limited [26–28].
Nitrates, short- and long-acting, have been studied in
patients with CMD with inconclusive results but there were
important differences in inclusion criteria of the study population. In our experience short-acting nitrates are often effective in relieving acute chest pain in patients with CMD, especially when administered on the background of a calcium
channel blocker or β-blocker. However, long-acting nitrates
incompletely control symptoms in CMD patients although
we continue to use them. We have observed that short-term
nitroglycerin ointment with an occlusive dressing to achieve
high doses may be helpful for some patients with exacerbations of resting angina to avoid hospitalization.
Beta-blockers, especially selective beta-1 blockers, including
nebivolol, have vasodilatory effects via nitric oxide production, resulting in increase of CFR [33]. In a study of 18
patients, doppler-flow-wire–derived coronary flow velocity
measurements were obtained in 10 controls and 8 patients
with CAD at rest and after intracoronary nebivolol. In the
CAD group, collateral flow was determined after dilatation
of a flow-limiting coronary stenosis. The investigators found
that intracoronary nebivolol increased CFR in both controls
and CAD patients [33].
Ranolazine blocks late sodium channels and decreases intracellular calcium, leading to cardiomyocyte relaxation and
thus, potentially improves CMD. The effect of ranolazine
has been controversial; in a randomized crossover trial of
128 patients (96% were women) with evidence of CMD,
confirmed using invasive coronary reactivity testing or noninvasive cardiac magnetic resonance imaging, myocardial
perfusion reserve index showed no differences in symptoms
or magnetic resonance perfusion reserve in the study cohort.
However, in a subsequent analysis of the study based on
baseline CFR on invasive testing, ranolazine showed benefit
in patients with reduced CFR at baseline [34, 35].
Angiotensin converting enzyme inhibitors (ACEIs) have been
shown to be beneficial in CMD by either directly affecting
the vascular function through the renin-angiotensin pathway

or indirectly by controlling blood pressure. ACEIs have been
associated with improved CFR and intracoronary Doppler
coronary flow measurements by increasing endothelial nitric
oxide bioavailability [36, 37]. In a sub-study of the National
Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE), 78 women with microvascular
dysfunction (coronary flow reserve < 3.0 following adenosine) and no obstructive CAD were randomly assigned to
either quinapril or a placebo treatment group. Sixty-one
women completed the 16-week treatment period with repeat
CFR measurements. ACEI was associated with significantly
improved CFR at 16 weeks. Regarding the secondary outcome in this sub-study, which assessed symptoms of angina,
both ACEIs (p = 0.037) and CFR increase (p = 0.008) contributed to symptom improvements [36].
Statins The benefit of statins comes from their cholesterollowering effect and also from their anti-inflammatory properties resulting in reduction of oxidative stress [26, 32, 38].
Statins reduce plaque lipid-rich core, macrophage, and foam
cell formation, decrease platelet reactivity and promote
fibrous cap thickening, leading to reduction in downstream
microembolization and thrombotic events [26]. In a recent
study from Denmark, 33,552 patients with non-obstructive
CAD from a large registry were evaluated using cardiac
computed tomography; investigators found that statins were
associated with improvement in rates of mortality or MI,
with the benefit being proportional to the burden of coronary
artery disease [39]. These findings are to be confirmed by
the ongoing Women’s IschemiA Trial to Reduce Events in
Non-ObstRuctIve CORonary Artery Disease (WARRIOR),
which is designed to assess the benefit of statins and ACEIs/
angiotensin receptor blocker (ARB) medical therapy as
well as additional interventions on MACE in symptomatic
women with INOCA, as discussed in a separate section [40].

4.2 Non‑Conventional Therapies
Studies have shown modest benefit from some of the nonconventional anti-anginal therapies [41–46]. Exercise
training modulates adrenergic and nitric oxide pathways,
potentially contributing to improvement in coronary flow
in CMD [41]. However, clinical trials proving the benefits
of exercise are challenging because of issues with patient
compliance and cost. Tricyclic antidepressant medications,
including imipramine, block multiple receptors, including
muscarinic acetylcholine receptors, potentially preventing
excessive constriction to acetylcholine, and they inhibit serotonin and norepinephrine reuptake. In a randomized trial of
60 patients with INOCA, imipramine improved symptoms
of angina, possibly by its analgesic effects on viscera; however, it did not affect quality of life [42, 43]. Spinal cord
stimulation has been associated with improvement in angina

CorMicA trial, n = 151 16% had vasospastic angina in the intervention group
(N = 75)

CorMicA trial, n = 151 16% had vasospastic angina in the intervention group
(N = 75)
CorMicA trial, n = 151, 57.3% had microvascular angina in the intervention
group (N = 75)

Calcium channel blockers

Nitrates

CorMicA trial, 151 patients, 57.3% had microvascular angina in the intervention group (N = 75)

CorMicA trial, n = 15, 57.3% had microvascular angina in the intervention
group (N = 75)
Danish registry including 33,552 patients

Randomized study, n = 26
Randomized study, n = 60
Study of 7 patients with refractory angina and normal coronaries
Randomized study, n = 26

ACEI/ARB

Statins

Physical training/exercise
Tricyclic antidepressants
Spinal cord stimulation
L-Arginine

CorMicA trial, for vasospastic angina, calcium channel blockers were associated
with improved angina scores (SAQ) at 6 months and 1 year [27, 47]
In another study of 16 pts (7 women), angiographically “normal” coronary arteries, IV diltiazem failed to improve CFR in those with reduced CFR [28]
CorMicA trial, for vasospastic angina, nitrates were associated with improved
angina scores (SAQ) at 6 months and 1 year [27, 47]
CorMicA trial, tailored treatment for microvascular dysfunction with beta
blocker (nebivolol) associated with improved angina scores (SAQ) at 6 months
and 1 year [27, 47]
In another study of 18 pts, Doppler-flow wire derived core blood flow velocity
measurements 10 controls and 8 pts with CAD, IV nebivolol increased CFR in
both controls and CAD patients [33]
Ranolazine is controversial; in patients with CMD confirmed using invasive
coronary reactivity testing or MPRI showed no differences in symptoms or
MPRI. However, in a sub analysis based on baseline CFR by invasive testing,
ranolazine showed benefit in patients with reduced CFR at baseline [34, 35]
CorMicA trial, tailored treatment for microvascular dysfunction with ACEI was
associated with improved angina scores (SAQ) at 6 months and 1 year [27, 47]
Sub-study NIH Women Ischemia Syndrome Evaluation (WISE) of 78 women
with INOCA and CFR < 3.0, 61 women completed study- ACEI (quinapril 80
mg/day) improved CFR at 16 weeks. Both ACEI and CFR increase contributed
to symptom improvement [36]
CorMicA trial, tailored treatment for microvascular dysfunction with statins was
associated with improved angina scores on SAQ over 6 months and 1 year [27,
47]
Cardiac CTA; statins were associated with improved mortality & MI, benefit
being proportional to burden of CAD [38]
Physical training associated with increased ex capacity and less angina [41]
Imipramine improved angina, possibly by visceral analgesic effect [42, 43]
Spinal cord stimulation associated improved angina and exercise tolerance [44]
l-Arginine improved angina and vascular function but associated with increased
MI in obstructive CAD [45]
HRT associated with improved chest pain and menopausal symptoms, but not
ischemia or brachial artery endothelial function. [46]

Supporting evidence

ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, CAD coronary artery disease, CFR coronary flow reserve, CMD coronary microvascular dysfunction, CTA
computed tomography angiography, FFR fractional flow reserve, HRT hormone replacement therapy, IMR index of microcirculatory resistance, INOCA ischemia with non-obstructive coronary
arteries, IV intravascular, MI myocardial infarction, MPRI myocardial perfusion reserve index, SAQ Seattle Angina Questionnaire

Low-dose hormonal therapy Randomized study, post-menopausal women from WISE, n = 35

Randomized cross-over trial, n = 128, 96% women

Ranolazine

Beta-blockers

Major studies, number (n) of patients

Therapy

Table 2  Summary of major therapies studied in coronary microvascular dysfunction (CMD) with supporting evidence
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and exercise tolerance [44]. Similarly, L-arginine seems to
improve angina and vascular function but was associated
with increased risk of myocardial infarction in patients with
obstructive CAD [45]. In a study of post-menopausal women
from WISE, low-dose hormonal therapy improved chest pain
symptoms, menopausal symptoms, and quality of life, but
was not associated with improved ischemia or endothelial
dysfunction [46].

5 The CorMicA Trial
With the knowledge gaps regarding the prevalence, optimal diagnostic approach, and management of patients with
CMD, the CorMicA trial was performed to answer some
of these questions. Indeed, we learned from the CorMicA
trial that non-obstructive CAD was more prevalent that we
initially thought (compromising 39% of all patients with
symptoms of myocardial ischemia), and that stratified medical therapy based on the type of CMD led to improvement
in symptoms and outcomes [27]. The CorMicA classified
151 patients with suspected CMD into the following types:
microvascular angina, vasospastic angina, or neither, based
on their invasive coronary assessment [27]. Briefly, invasive coronary testing involved passing a pressure wire via a
guiding catheter (typically into the left anterior descending
coronary artery) for assessment of coronary flow reserve
(abnormal < 2.0), the index of microcirculatory resistance (abnormal ≥ 25), and fractional flow reserve (abnormal ≤ 0.80) during intravenous infusion of adenosine (140
μg/kg/min). Incremental concentrations of acetylcholine
(10−6, 10−5, 10−4 mol/L) were then sequentially infused during 2-min periods, followed by vasospasm provocation testing (acetylcholine bolus, 100 μg for left coronary system or
50 μg for right coronary artery), and finally 300 μg of glyceryl trinitrate. While vasospastic angina was defined as epicardial vasoconstriction ≥ 90% in response to acetylcholine
with reproduction of the usual chest pain and ischemic electrocardiographic changes, microvascular angina was defined
based on the standardized Coronary Vasomotion Disorders
International Study Group (COVADIS) as symptoms of
myocardial ischemia, non-obstructive CAD, and evidence
of microvascular dysfunction by abnormal microvascular
resistance, coronary flow reserve or microvascular spasm.
A total of 151 patients were randomized; patients in
the intervention group (N = 75 patients) were assigned to
specific management strategy based on their type, while
patients in the control group (N = 76 patients) received
the concurrent standard of care. Of the intervention group,
57.3% had microvascular angina, compared with 46.1% in
the control group. On the other hand, 16% of the intervention group and 17.1% of the control group had vasospastic angina. Mixed microvascular angina and vasospastic

angina was present in 18.7% in the intervention group and
22.4% in the control group. Neither endotype was found
in 8% in the intervention group and 14.5% in the control group [27, 47]. In the intervention group, patients
with vasospastic angina were prescribed calcium channel
blockers and/or nitrates, while patients with microvascular angina were prescribed beta-blockers with consideration of ACEIs and statins. Patients with neither type
were deemed patients with non-cardiac chest pain, and
were discharged from cardiology clinic and anti-anginal
medications were discontinued (Fig. 2). The intervention
resulted in a mean improvement of 11.7 U in the Seattle
Angina Questionnaire summary score at 6 months (95%
CI 5.0–18.4; p = 0.001). In addition, the intervention led
to improvements in the mean quality-of-life score (EQ5D index 0.10 U; 95% CI 0.01–0.18; p = 0.02) and visual
analogue score (14.5 U; 95% CI 7.8–21.3; p < 0.001).
There were no differences in MACE (composite of allcause mortality, myocardial infarction, unstable angina
hospitalization or revascularization, heart failure hospitalization, and cerebrovascular event) at the 6-month followup (2.6% controls vs 2.6% intervention; p = 1.00) [27].
Similarly, at 1-year follow-up, 142 patients completed
the Seattle Angina Questionnaire assessment and overall angina (Seattle Angina Questionnaire summary score)
improved in the intervention group by 27% (difference
13.6 units; 95% CI 7.3–19.9; p < 0.001). Quality of life
(EQ-5D index) improved in the intervention group relative
to the control group (mean difference 0.11 units [18%];
95% CI 0.03–0.19; p = 0.01). After a median follow-up
duration of 19 months, occurrence of a MACE was similar
between the groups, occurring in 9 subjects (12%) in the
intervention group and 8 (11%) in the control group (p =
0.80) [47]. Using this strategy, physicians were more likely
to prescribe anti-anginal medications in the intervention
group. Similarly, patients were more likely to take calcium
channel blockers at 6 months in the intervention group.
The CorMicA trial showed that stratified therapy based
on the type of microvascular dysfunction led to improvement in angina and quality of life. Patients with coronary
vasospasm showed benefit from vasodilator therapy with
calcium channel blockers and/or nitrate therapy, while
patients with microvascular angina experienced improvement in their symptoms with beta-blockers and consideration of ACEI/statin therapy [27, 47].

6 Knowledge Gaps and Ongoing Trials
While CorMicA showed evidence supporting the benefit of
an algorithmic approach to patients with suspected CMD
with stratified treatment based on the specific endotype
of CMD, CMD remains a heterogenous clinical condition

Coronary Microvascular Dysfunction in Patients with Non-Obstructive Coronary Arteries

Fig. 2  Summary of diagnosis and treatment of coronary microvascular dysfunction (CMD) based on the CorMicA trial. ACEI angiotensin-converting enzyme inhibitor, CFR coronary flow reserve, FFR fractional flow reserve, IMR index of microcirculatory resistance

with knowledge gaps in understanding the pathophysiology,
potential disease mechanisms, interactions of different risk
factors, and optimal management options with their impact
on outcomes as well as prognosis of different types of CMD
[27, 47]. Studies have shown that INOCA is associated with
higher risk of developing HFpEF, through potential mechanisms including aortic stiffness and ventricular remodeling.
However, this association is not completely understood and
future studies addressing this knowledge gap are needed [22,
23]. Observational studies have shown potential benefit of
ACEIs and statins, as well as beta-blockers; however, the
benefit of these medications compared to no medication
has not been confirmed in large randomized clinical trials
[26, 28, 32, 35–37]. Thus, large randomized clinical trials
are needed to confirm the benefit and role of the different
pharmacological and behavioral treatments. There are a few
ongoing trials in this arena to address the optimal therapy
in patients with CMD. The WARRIOR (ClinicalTrials.gov
NCT03417388) is a multicenter, randomized, blinded outcome trial to evaluate the benefit of statin and ACEI/ARB
therapy on MACE in symptomatic women with INOCA
[40]. The Precision Medicine With Zibotentan in Microvascular Angina (PRIZE) (ClinicalTrials.gov NCT04097314)
is another trial assessing the benefit of zibotentan, an oral

endothelin A receptor antagonist, in patients with microvascular dysfunction [48]. The CorCTCA (ClinicalTrials.gov
NCT 03477890) is an ongoing trial aiming to clarify the
prevalence and outcomes of INOCA when standard care is
based on coronary computed tomography angiography [49].

6.1 The WARRIOR Trial
Given the scarcity of strong evidence evaluating the optimal
therapy in women with signs and/or symptoms of suspected
ischemia and non-obstructive CAD, as our current data are
mainly based on observational studies with the exception
of CorMicA trial, the WARRIOR trial was designed to
assess the benefit of intensive medical therapy with high
intensity statin and ACEIs or angiotensin receptor blocker
therapy versus the usual care in a multicenter prospective
randomized blinded outcome study (Fig. 3) [40]. In addition to the former statins and ACEIs/ARB therapy, women
will receive aspirin if there is no contraindication or high
bleeding risk, behavioral lifestyle assessment and counseling with weight loss, exercise, and smoking cessation,
as well as quality-of-life questionnaires. The hypothesis
of this trial is that the intensified medical therapy will
reduce MACE compared with the usual care. The primary

I. Y. Elgendy et al.

Fig. 3  Summary of the WARRIOR trial design. ACEI angiotensin
converting enzyme inhibitor, ARB angiotensin receptor blocker, CAD
coronary artery disease, CV cardiovascular, INOCA ischemia with

non-obstructive coronary arteries, SAQ Seattle Angina Questionnaire,
US United States

outcome is the composite of death, nonfatal myocardial
infarction, nonfatal stroke/transient ischemic attack, or hospitalization for heart failure or angina. Secondary outcomes
include quality of life, cardiovascular death, angina, time
to "return to duty/work", health resource consumption, and
primary outcome components. Enrollment was started in
2018 and the estimated completion time is December 2022,
with 4422 enrolled over 4 years from 50 sites in the USA.
The study will evaluate the benefits of these medications
and interventions in patients with INOCA and could potentially contribute to practice-changing recommendations by
providing strong scientific evidence confirming the benefit
of these medications in INOCA patients and potentially
implementing guideline recommendations regarding the
management of these patients [40].

diagnose these clinical entities. Importantly, medical stratification based on the type of condition has shown benefit
in improving angina in these patients. The WARRIOR trial
is a promising landmark trial, which is currently enrolling
patients and will address some of the unanswered questions
for management of women with INOCA. Nevertheless, it is
important to understand that there are many other knowledge
gaps in this field and randomized clinical trials are needed
to help us address some of these.

7 Summary and Conclusions
Coronary microvascular dysfunction has been increasingly
recognized as a heterogenous clinical entity with different
subtypes and response to treatment. Knowledge of the diagnostic evaluation, including invasive assessment, is key to
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